APOA4

Across TCGA pan-cancer cohorts, APOA4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated APOA4 data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher APOA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated APOA4 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

HNSC, CHOL, and BLCA are the cancer types where APOA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.200	0.752	<.001	48	view →
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
BLCA	DFS	Median	All	0.248	0.630	.001	12	view →
CESC	DFS	Median	IV	0.053	0.529	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	All	1.000	0.354	.049	3	view →
LUSC	OS	Median	II,III,IV	0.315	0.619	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

APOA4–HNSC (OS)

Open the HNSC breakdown →